Gain Therapeutics (GANX) Deferred Taxes (2020 - 2025)
Gain Therapeutics (GANX) posted quarterly Deferred Taxes of -$14843.0 for Q4 2025, up 98.34% year-over-year from -$7483.4 in Q4 2024, and up 18.62% quarter-over-quarter from -$18239.0 in Q3 2025.
Gain Therapeutics (GANX) Deferred Taxes (2020 - 2025) Analysis & Trends
Gain Therapeutics' Deferred Taxes history runs 6 years deep, the most recent figure standing at -$14843.0 for Q4 2025.
- In Q4 2025, Deferred Taxes rose 98.34% year-over-year to -$14843.0; the TTM figure through Dec 2025 stood at -$328071.0 (up 61.62% YoY), while the FY2025 annual figure was -$328071.0, up 61.62% from the prior year.
- Deferred Taxes for Q4 2025 stood at -$14843.0, up from -$18239.0 in the prior quarter.
- The five-year high for Deferred Taxes was $1.6 million in Q2 2023, with the low at -$896566.0 in Q4 2024.
- The 5-year median for Deferred Taxes is -$48167.0 (2021), against an average of -$13556.6.
- The sharpest annual moves came in 2023 and 2025: Deferred Taxes jumped 1440.01% in 2023, then tumbled 113909.94% in 2025.
- Gain Therapeutics' Deferred Taxes stood at -$53507.0 in 2021, then jumped by 98.86% to -$608.0 in 2022, then plunged by 62139.97% to -$378419.0 in 2023, then slumped by 136.92% to -$896566.0 in 2024, then jumped by 98.34% to -$14843.0 in 2025.
- Business Quant data shows GANX's Deferred Taxes at -$14843.0 in Q4 2025, -$18239.0 in Q3 2025, and -$206358.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 2.66 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | - |
| 10 | Gain Therapeutics | 87.47 Mn | 87.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -14,843.00 |
| Sep 30, 2025 | -18,239.00 |
| Jun 30, 2025 | -206,358.00 |
| Mar 31, 2025 | -88,631.00 |
| Dec 31, 2024 | -896,566.00 |
| Sep 30, 2024 | 236.00 |
| Jun 30, 2024 | -181.00 |
| Mar 31, 2024 | 41,798.00 |
| Dec 31, 2023 | -378,419.00 |
| Sep 30, 2023 | -129,283.00 |
| Jun 30, 2023 | 1.65 Mn |
| Mar 31, 2023 | -55,180.00 |
| Dec 31, 2022 | -608.00 |
| Sep 30, 2022 | -21,429.00 |
| Jun 30, 2022 | -122,997.00 |
| Mar 31, 2022 | -63,309.00 |
| Dec 31, 2021 | -53,507.00 |
| Sep 30, 2021 | -42,827.00 |
| Jun 30, 2021 | 192,100.00 |
| Mar 31, 2021 | -61,065.00 |